Search | Clinical Trials Finder

Conditions: Human Immuno-deficiency Virus (HIV) Disease
Interventions: Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Peyronie's Disease
Interventions: Subjects Previously Treated with AA4500; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Anchorage, Alaska • Burbank, California • Laguna Hills, California + 27 more

Conditions: PreDiabetes, Type 2 Diabetes
Interventions: 16-Week Diabetes Prevention Program for Mothers and Children; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 8 Years to 54 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Diseases
Interventions: Rosuvastatin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Allergic Rhinitis
Interventions: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control; Biological · Other
Lead sponsor: Immunomic Therapeutics, Inc.; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Familial Cold Autoinflammatory Syndrome (FCAS), Familial Cold Urticaria, Muckle-Wells Syndrome (MWS), Genetic Diseases, Inborn
Interventions: rilonacept 160 mg, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 7 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 24
States / cities: Little Rock, Arkansas • Palm Desert, California • Upland, California + 21 more

Conditions: Bone Infection, Joint Infection, Bone and Joint Infection
Interventions: Omadacycline Pill, Standard of Care; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Insomnia, Shift-Work Related Sleep Disturbance
Interventions: Cognitive Behavioral Therapy for Insomnia for Firefighters (CBT-I-F), Fitbit Inspire HR Wrist Worn Device (NCT04176926); Behavioral · Device
Lead sponsor: Pacific University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Forest Grove, Oregon

Conditions: Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions: Glycerinated peanut allergenic extract, Placebo for peanut extract (glycerin); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more

Conditions: Multiple Sclerosis
Interventions: No Treatment Arm, Topical Preparation H arm; Other · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Sacramento, California • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more

Conditions: Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
Interventions: KB109, No intervention; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Torrance, California • Atlanta, Georgia • Augusta, Georgia + 5 more

Conditions: Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Patient Engagement
Interventions: CKD "What You Need To Know" Workbook System, CKD Action Plan, CKD Web-based Resource List, Food Label reading exercise; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 105 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: methylphenidate, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 21 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1986 – 1994
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pyoderma Gangrenosum
Interventions: Platelet rich plasma therapy; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Epilepsy
Interventions: Brivaracetam; Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 16 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more

Conditions: Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
Interventions: nilotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 10
States / cities: Loma Linda, California • Palo Alto, California • Orlando, Florida + 7 more

Conditions: Chronic Kidney Disease
Interventions: Education, Daily weight measurement and monitoring, Universal Dietary education, Medication review, Focused advanced directive program, Countdown to fistula program; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Great Neck, New York

Conditions: Volume Loss (Soft Tissue Ptosis or Atrophy )
Interventions: Hyperdiluted Calcium Hydroxylapatite, Calcium hydroxylapatite, Calcium hydroxylapatite with integral lidocaine; Device
Lead sponsor: Kalpna Kay Durairaj, MD, FACS; Other
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Chronic Heart Failure, Iron Deficiencies
Interventions: Ferric Derisomaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Infections, Human Immunodeficiency Virus and Tuberculosis
Interventions: GSK1349572, Placebo, Iohexol Injection, Para-aminohippurate infusion; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD, Ruxolitinib 1.5% Cream BID, Triamcinolone 0.1% Cream BID, Vehicle Cream BID; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Birmingham, Alabama • Bryant, Arkansas • Encino, California + 28 more

Conditions: Ulcerative Colitis (UC)
Interventions: Ulcerative Colitis Diet, Antibiotic cocktail; Other · Drug
Lead sponsor: Prof. Arie Levine; Government
Eligibility: 8 Years to 19 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Interventions: Giredestrant, Fulvestrant, Abemaciclib, Palbociclib, Ribociclib, LHRH Agonist, FoundationOne Liquid CDx Assay (F1LCDx); Drug · Diagnostic Test
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 61
States / cities: Daphne, Alabama • Auburn, California • Greenbrae, California + 53 more

Search by objective public record fields.

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease

Type 2 Diabetes Prevention in Community Health Care Settings for at Risk Children and Mothers

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection

A Pilot Study of Cognitive Behavioral Therapy - Insomnia (CBT-I) Among Professional Firefighters

A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms

A Pragmatic Approach to CKD Patient Education

Further Studies of Attention Deficit Disorder - Residual Type (RT)

Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.

Healthy Transitions in Late Stage Kidney Disease

Restoring Facial Volume After GLP-1 Weight Loss With Radiesse

Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure

A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)